Financial Analysis: Day One Biopharmaceuticals Inc (DAWN)’s Ratios Unveil Key Insights

Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

As of close of business last night, Day One Biopharmaceuticals Inc’s stock clocked out at $13.27, down -2.43% from its previous closing price of $13.60. In other words, the price has decreased by -$2.43 from its previous closing price. On the day, 1.11 million shares were traded. DAWN stock price reached its highest trading level at $13.85 during the session, while it also had its lowest trading level at $13.0.


To gain a deeper understanding of DAWN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.93 and its Current Ratio is at 10.93. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on April 24, 2024, Reiterated its Buy rating but revised its target price to $33 from $30 previously.

On April 25, 2023, BofA Securities Downgraded its rating to Underperform which previously was Buy and also lowered its target price recommendation from $34 to $9.

On February 08, 2023, CapitalOne started tracking the stock assigning a Overweight rating and target price of $40.CapitalOne initiated its Overweight rating on February 08, 2023, with a $40 target price.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 16 ’24 when Bender Jeremy sold 7,873 shares for $16.08 per share. The transaction valued at 126,588 led to the insider holds 654,728 shares of the business.

Dubow Adam sold 3,253 shares of DAWN for $52,304 on May 16 ’24. The GENERAL COUNSEL now owns 21,731 shares after completing the transaction at $16.08 per share. On May 16 ’24, another insider, York Charles N II, who serves as the COO, CFO AND SECRETARY of the company, sold 2,675 shares for $16.08 each. As a result, the insider received 43,011 and left with 224,868 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DAWN now has a Market Capitalization of 1159664128 and an Enterprise Value of 842019456.

Stock Price History:

Over the past 52 weeks, DAWN has reached a high of $18.07, while it has fallen to a 52-week low of $9.67. The 50-Day Moving Average of the stock is -13.63%, while the 200-Day Moving Average is calculated to be -4.82%.

Shares Statistics:

It appears that DAWN traded 1.13M shares on average per day over the past three months and 845800 shares per day over the past ten days. A total of 87.23M shares are outstanding, with a floating share count of 60.58M. Insiders hold about 30.68% of the company’s shares, while institutions hold 73.19% stake in the company. Shares short for DAWN as of 1715731200 were 10599135 with a Short Ratio of 9.39, compared to 1713139200 on 8941942. Therefore, it implies a Short% of Shares Outstanding of 10599135 and a Short% of Float of 15.14.

Most Popular